For some types of tumor, neoadjuvant ICI therapy is standard and/or about to be approved. Special care must be taken in managing ICI toxicity. In view of the adverse effects and cost of ICI, it will be important to identify biomarkers for a higher likelihood of benefit.
Hofheinz et al. (Fri,) studied this question.